Company intelligence / Profile preview

Preclina

Seoul, Seoul, South Koreapreclina.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Preclina is an active preclinical contract research organization specializing in immunology, autoimmune, and inflammatory disease models. It provides high-throughput cell-based evaluation using patient-derived cells and humanized animal models to support biotech/pharma clients with drug discovery and diagnostic technology development. The company is recognized for its expertise in both in vitro and in vivo preclinical modeling. No clinical results are reported as it does not develop its own therapeutics.

Therapeutic areas: Immunology
Modalities: Cell-based assaysHumanized animal modelsPatient-derived primary cellsIn vitro and in vivo models for immunology/inflammation research
Industry: Drug Discovery Services

Partnerships

abc biopply AG – strategic collaboration on humanized preclinical model platforms

Beyond the preview

Go deeper on Preclina.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Preclina.

Explore the full profile